Patents Assigned to Hadasit Medical Research Services & Development Ltd.
-
Patent number: 9034814Abstract: The present invention provides novel uses for CXCR4 antagonists, including specifically peptides of the T-140 family, in the treatment of skin burns and other injuries. The invention further provides methods for increasing epithelialization in a subject in need thereof, and for preventing or inhibiting fibrosis and excessive scar formation, using peptide inhibitors of the T-140 family as well as other CXCR4 antagonists.Type: GrantFiled: May 21, 2006Date of Patent: May 19, 2015Assignees: Hadasit Medical Research Services and Development Ltd., Kyoto UniversityInventors: Amnon Peled, Nobutaka Fujii
-
Publication number: 20150125506Abstract: The present invention concerns RPE cells obtainable by directed differentiation from stem cell, particularly, human stem cells. It has been specifically found that culturing stem cells in the presence of one or more member of the TGF? superfamily, such as Activin A) induced directed differentiation into mature and functional RPE cells. This was evidenced by the expression of markers specific to mature RPE cells, including MiTF-A, RPE65 or Bestrophin). In accordance with one particular embodiment, the cells are a priori cultured with nicotinamide (NA) which was found to augment the cells' response to the inductive effect of the one or more member of the TGF? superfamily. The invention also provides methods of performing the directed differentiation, as well as methods for use of the resulting RPE cells.Type: ApplicationFiled: December 29, 2014Publication date: May 7, 2015Applicant: HADASIT MEDICAL RESEARCH SERVICES AND DEVELOPMENT LTD.Inventors: Masha IDELSON, Ruslana ALPER-PINUS, Alex OBOLENSKY, Eyal BANIN, Benjamin Eithan REUBINOFF
-
Publication number: 20150118749Abstract: The present invention concerns RPE cells obtainable by directed differentiation from stem cell, particularly, human stem cells. It has been specifically found that culturing stem cells in the presence of one or more member of the TGF? superfamily, such as Activin A) induced directed differentiation into mature and functional RPE cells. This was evidenced by the expression of markers specific to mature RPE cells, including MiTF-A, RPE65 or Bestrophin). In accordance with one particular embodiment, the cells are a priori cultured with nicotinamide (NA) which was found to augment the cells' response to the inductive effect of the one or more member of the TGF? superfamily. The invention also provides methods of performing the directed differentiation, as well as methods for use of the resulting RPE cells.Type: ApplicationFiled: December 29, 2014Publication date: April 30, 2015Applicant: HADASIT MEDICAL RESEARCH SERVICES AND DEVELOPMENT LTD.Inventors: Masha IDELSON, Ruslana ALPER-PINUS, Alex OBOLENSKY, Eyal BANIN, Benjamin Eithan REUBINOFF
-
Patent number: 8986929Abstract: The present invention identifies genotypes associated with resistance to extrapyramidal symptoms induced by antipsychotic drugs. The present invention further identifies genotypes associated with predisposition to the onset or aggravation of extrapyramidal symptoms induced by antipsychotic drugs and use thereof for assessment of patient populations. Specifically, the present invention relates to particular polymorphisms in the RGS2 gene that are associated with resistance or susceptibility to drug-induced extrapyramidal symptoms.Type: GrantFiled: June 7, 2011Date of Patent: March 24, 2015Assignee: Hadasit Medical Research Services and Development Ltd.Inventors: Bernard Lerer, Lior Greenbaum
-
Patent number: 8980244Abstract: The invention relates to use of the natural cytotoxicity receptor NKp46 for preventing and treating diabetes, including type I diabetes (TID) and type 2 diabetes. In particular, the invention provides compositions comprising a fragment of the extracellular region of NKp46 for preventing the onset and progression of diabetes.Type: GrantFiled: April 15, 2013Date of Patent: March 17, 2015Assignees: Ben-Gurion University of the Negev Research and Development Authority, Hadasit Medical Research Services and Development Ltd., Yissum Research Development Company of the Hebrew University of Jerusalem, Ltd.Inventors: Ofer Mandelboim, Angel Porgador, Yaakov Naparstek, Chamutal Gur
-
Patent number: 8975294Abstract: The present invention relates to methods kits and combined compositions using DFO-metal complexes, specifically, Zinc-desferrioxamine (Zn-DFO), gallium-desferrioxamine (Ga-DFO) complexes and any combinations thereof for preventing, treating, ameliorating or inhibiting an immune-related disorder, specifically, a skin-related inflammatory disorder such as psoriasis, an inflammatory respiratory condition such as asthma, and an autoimmune disease such as diabetes and any immune-related disorder.Type: GrantFiled: August 19, 2010Date of Patent: March 10, 2015Assignees: Hadasit Medical Research Services and Development Ltd., Yissum Research Development Company of the Hebrew University of Jerusalem Ltd.Inventors: Mordechai Chevion, Vladimir Vinokur, Eduard Berenshtein, Ron Eliashar, Baruch Bulvik
-
Patent number: 8956866Abstract: The present invention concerns RPE cells obtainable by directed differentiation from stem cell, particularly, human stem cells. It has been specifically found that culturing stem cells in the presence of one or more member of the TGF? superfamily, such as Activin A) induced directed differentiation into mature and functional RPE cells. This was evidenced by the expression of markers specific to mature RPE cells, including MiTF-A, RPE65 or Bestrophin). In accordance with one particular embodiment, the cells are a priori cultured with nicotinamide (NA) which was found to augment the cells' response to the inductive effect of the one or more member of the TGF? superfamily. The invention also provides methods of performing the directed differentiation, as well as methods for use of the resulting RPE cells.Type: GrantFiled: April 27, 2008Date of Patent: February 17, 2015Assignee: Hadasit Medical Research Services and Development Ltd.Inventors: Masha Idelson, Ruslana Alper-Pinus, Alex Obolensky, Eyal Banin, Benjamin Reubinoff
-
Publication number: 20140341952Abstract: A method for treating a disease comprising administering to a mammal in need thereof an effective dosage of an extract of a plant of the genus Hoodia, wherein the disease is selected from the group consisting of immune-mediated disorders, immune-associated disorders, inflammatory diseases, coronary disease, insulin resistance and liver-related diseases. In a preferred embodiment, the Hoodia is Hoodia parviflora. Also disclosed is a pharmaceutical composition for treating the above diseases comprising an effective dosage of an extract of a plant of the genus Hoodia.Type: ApplicationFiled: December 19, 2013Publication date: November 20, 2014Applicants: HADASIT MEDICAL RESEARCH SERVICES & DEVELOPMENT LTD., BIO-MASS LTD., DESERT LABS AGRICULTURE COOPERATIVE ASSOCIATION LTD.Inventors: Refael Aharon, Yaron Ilan
-
Patent number: 8868194Abstract: The present invention depicts an implantable artificial pacemaker (AAP) comprising oscillatory means providing pulsating signals at a pre-selected frequency, wherein the pacemaker is pacing the aorta. The invention also describes an AAP further comprising; (i) a plurality of sensors disposed internally or externally to the aorta; and (ii) a pacing means in which the AAP stimulates the aortic media, augmenting physiological aortic elastic recoil. An AAP further comprising a processor capable of obtaining information from sensors and triggering an appropriate contraction wave in the aortic media is also introduced. A method of managing aortic rhythm comprising; (i) implanting an AAP comprising oscillatory means; and (ii) pulsating signals at a preselected frequency, so as to pace the aorta and in which the pulsating signals are provided by synchronizing and coordinating activation impulses in a portion of the aorta using electrical impulses is also taught.Type: GrantFiled: March 29, 2007Date of Patent: October 21, 2014Assignee: Hadasit Medical Research Services and Development Ltd.Inventors: Amos Cahan, David Planer
-
Patent number: 8865909Abstract: Novel agents exhibiting anti-biofilm formation activity while being non-cytotoxic are provided, as well as methods of using the same, either per se or conjugated to a polymer, for preventing and/or reducing the formation of microbial biofilms and/or for disrupting microbial biofilms. The novel agents described herein include thiazolidine-2,4-diones (TZDs), pyrrolidine-2,5-diones (PYDs), imidazolidine-2,4-diones or oxazolidine-2,4-diones, substituted by an alkyl having 7-20 carbon atoms in its backbone chain.Type: GrantFiled: November 19, 2009Date of Patent: October 21, 2014Assignees: Yissum Research Development Company of the Hebrew University of Jerusalem Ltd., Hadasit Medical Research Services and Development Ltd.Inventors: Morris Srebnik, Itzhack Polacheck, Doron Steinberg, Adel Jabbour, Edward Sionov
-
Publication number: 20140255403Abstract: This application describes a method of delivering a TNF antagonist molecule, in a biologically active form, to a subject in need thereof, the method comprising, orally or mucosally administering to the subject a therapeutically effective amount of a TNF antagonist molecule. This application further describes a method of treating, preventing or reducing the severity of obesity, the method comprising, administering to the subject a therapeutically effective amount of a TNF antagonist molecule.Type: ApplicationFiled: March 6, 2014Publication date: September 11, 2014Applicant: HADASIT MEDICAL RESEARCH SERVICES & DEVELOPMENT LTD.Inventor: Yaron ILAN
-
Combination Therapy of Beta-Glycolipids and Antibodies for the Treatment of Immune-Related Disorders
Publication number: 20140255420Abstract: The present invention relates to a combination therapy for the treatment of immune-related disorders. More particularly, the invention relates to oral or mucosal synergistic compositions combining beta-glycolipids, preferably, ?-glycosphin-golipids with immunoglobulin molecules specific for at least one antigen derived from a component of the immune system, specifically an anti-CD3 antibody. The invention further provides methods kits and uses of the combined compositions of the invention for immune-modulation and thereby for the treatment of immune-related disorders. In a preferred embodiment, anti-CD3 antibody (OKT3) is orally administered in combination with ?-glucosylceramide (also known as glycocerebroside) in an animal model of type 2 diabetes.Type: ApplicationFiled: February 18, 2014Publication date: September 11, 2014Applicants: THE BRIGHAM AND WOMEN'S HOSPITAL, INC., HADASIT MEDICAL RESEARCH SERVICES AND DEVELOPMENT LTD.Inventors: Yaron Ilan, Howard L. Weiner -
Patent number: 8804904Abstract: A physical phantom reference to control for variability of computed tomography measurement results duplicates the density curve of blood perfusion of contrast material in a healthy aorta or large artery to normalize observed changes in healthy arterial blood perfusion when calculating the reduction in tumor blood perfusion between two examination times. In one embodiment, a plurality of compartments with different concentrations of contrast material corresponding to a density curve of blood perfusion of a healthy tissue are positioned-in a screening field of a CT machine so the CT machine images the compartments when it images the healthy tissue. In another embodiment, a pipe containing fluid receives an injection of contrast material from the injector when the injector injects the contrast material into the patient, the pipe having sections of varying diameter so the sections together correspond to a blood perfusion curve of the contrast material in a healthy tissue.Type: GrantFiled: December 24, 2013Date of Patent: August 12, 2014Assignee: Hadasit Medical Research Services and Development Ltd.Inventors: Aviv Hirschenbain, Jacob Sosna
-
Publication number: 20140114176Abstract: A physical phantom reference to control for variability of computed tomography measurement results duplicates the density curve of blood perfusion of contrast material in a healthy aorta or large artery to normalize observed changes in healthy arterial blood perfusion when calculating the reduction in tumor blood perfusion between two examination times. In one embodiment, a plurality of compartments with different concentrations of contrast material corresponding to a density curve of blood perfusion of a healthy tissue are positioned-in a screening field of a CT machine so the CT machine images the compartments when it linages the healthy tissue. In another embodiment, a pipe containing fluid receives an injection of contrast material from the injector when the injector injects the contrast material into the patient, the pipe having sections of varying diameter so the sections together correspond to a blood perfusion curve of the contrast material in a healthy tissue.Type: ApplicationFiled: December 24, 2013Publication date: April 24, 2014Applicant: HADASIT MEDICAL RESEARCH SERVICES AND DEVELOPMENT LTDInventors: Aviv HIRSCHENBAIN, Jacob SOSNA
-
Patent number: 8686041Abstract: The invention relates to inhibition of ornithine aminotransferase (OAT) for suppression of tumor cells proliferation. More particularly, the invention relates to methods of treatment of proliferative disorders by the selective inhibition of OAT, and further provides the use of OAT inhibitors, specifically, 5-amino-1,3-hexadienyl-carboxylic acid (Gabaculine), and Gabaculine analogue 8, for compositions and methods for the treatment of proliferative disorders such as hepatocellular carcinoma. The invention further provides methods and kits for the diagnosis of a pathologic proliferative disorder in a mammalian subject, based on determining the level of OAT expressed in a biological sample obtained from a subject.Type: GrantFiled: May 31, 2012Date of Patent: April 1, 2014Assignees: Hadasit Medical Research Services & Development, Ltd., Northwestern UniversityInventors: Yaron Ilan, Ehud Zigmond, Richard B. Silverman, Hejun Lu
-
Patent number: 8680148Abstract: Methods for treating a bacterial infection by using a metallo-desferrioxamine complex.Type: GrantFiled: August 13, 2007Date of Patent: March 25, 2014Assignees: University of Washington, Hadasit Medical Research Services and Development Ltd., Yissum Research Development Company of the Hebrew University of Jerusalem Ltd.Inventors: E. Peter Greenberg, Ehud Banin, Eyal Banin, Eduard Berenshtein, Mordechai Chevion
-
Publication number: 20140080782Abstract: A method of diagnosing pancreatic cancer in a subject is provided. The method comprising determining a level and/or activity of at least one saliva secreted marker in a saliva sample of the subject wherein an alteration in said marker with respect to an unaffected saliva sample is indicative of the pancreatic cancer.Type: ApplicationFiled: December 13, 2011Publication date: March 20, 2014Applicant: Hadasit Medical Research Services and Development Ltd.Inventors: Aaron Palmon, Omer Deutsch, Doron Aframian, Oren Lahav
-
Patent number: 8636411Abstract: A physical phantom reference to control for variability of computed tomography measurement results duplicates the density curve of blood perfusion of contrast material in a healthy aorta or large artery to normalize observed changes in healthy arterial blood perfusion when calculating the reduction in tumor blood perfusion between two examination times. In one embodiment, a plurality of compartments with different concentrations of contrast material corresponding to a density curve of blood perfusion of a healthy tissue are positioned-in a screening field of a CT machine so the CT machine images the compartments when it images the healthy tissue. In another embodiment, a pipe containing fluid receives an injection of contrast material from the injector when the injector injects the contrast material into the patient, the pipe having sections of varying diameter so the sections together correspond to a blood perfusion curve of the contrast material in a healthy tissue.Type: GrantFiled: February 3, 2010Date of Patent: January 28, 2014Assignee: Hadasit Medical Research Services and Development Ltd.Inventors: Jacob Sosna, Aviv Hirschenbain
-
Patent number: 8617561Abstract: An article of manufacture comprising packaging material and a pharmaceutical composition is disclosed, the article of manufacture being identified in print in or on the packaging material for treatment of an immunity-related disease in a subject in need thereof. The pharmaceutical composition comprises a pharmaceutically acceptable carrier and, as an active ingredient, a compound being capable of modulating an interaction between a heparin-binding domain of a thrombospondin and a receptor of the heparin-binding domain.Type: GrantFiled: June 20, 2006Date of Patent: December 31, 2013Assignees: Hadasit Medical Research Services and Development Ltd., Yissum Research Development Company of the Hebrew University of JerusalemInventors: Dror Mevorach, Alon Krispin, Yaniv Bledi, Michal Linial
-
Publication number: 20130314669Abstract: A method of diagnosis is disclosed. The method comprises using a display device for presenting a motion perception test to a subject and determining a subject response to the motion perception test. The response can be used for assessing presence or absence of demyelination and/or remyelination.Type: ApplicationFiled: October 18, 2012Publication date: November 28, 2013Applicant: Hadasit Medical Research Services and Development Ltd.Inventors: Netta LEVIN, Noa Raz, Tamir Ben-Hur